Article

Wavefront-guided outcomes satisfactory for hyperopia or mixed astigmatism

The U.S. Multicenter Trials of wavefront-guided treatment of hyperopia and mixed astigmatism with the CustomView Ablation System (VISX) indicated that 9 months after treatment both groups had similar good results and patients expressed high levels of satisfaction with the outcomes.

Paris—The U.S. Multicenter Trials of wavefront-guided treatment of hyperopia and mixed astigmatism with the CustomView Ablation System (VISX) indicated that 9 months after treatment both groups had similar good results and patients expressed high levels of satisfaction with the outcomes.

In this study, 112 eyes (56 patients) were treated bilaterally with wavefront-guided LASIK and targeted for emmetropia. The mean patient age was 52 years; the mean sphere was 2 D, the mean cylinder was 0.7 D, and the mean spherical equivalent was 2.4 D, according to Douglas Koch, MD, of Houston, at the annual meeting of the European Society of Cataract and Refractive Surgeons.

"At 6 months postoperatively in the hyperopic group (26 eyes), the mean uncorrected visual acuity (UCVA) levels were 70% with 20/20 or better and 88% 20/25 and at 9 months postoperatively 79% had 20/20 or better and 93% 20/25 or better. At 6 months 95% of eyes were ±1 D of intended correction and 83% were ±0.5 D. Up to 9 months postoperatively, the stability was good," he reported.

One eye lost more than one line of best spectacle-corrected visual acuity (BSCVA) and no eyes lost more than two lines of visual acuity.

"In the mixed astigmatism group (86 eyes), the visual acuity results and the accuracy were comparable to the hyperopic group. The mean sphere decreased from -1.68 to 0.9 D. The cylinder decreased from about 3 D to about 0.5 D. Seventy-seven percent of eyes were within ±0.5 D of the intended sphere, and 56% were within ±0.5 D of the intended cylinder," Dr. Koch reported. In both groups, there was a significant increase in patient satisfaction from preoperatively to postoperatively.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
© 2024 MJH Life Sciences

All rights reserved.